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ABSTRACT 
 
 
L-proline is a non-essential amino acid and one of the major amino acid 
constituents of extracellular fluid. Specific mutations in genes that control proline 
metabolism lead to hyperprolinemia which is characterized by an increase in the level of 
blood and cerebrospinal fluid concentration of l-proline. In fact, deletion or mutation of 
the PRODH gene which codes for proline oxidase (POX) / proline dehydrogenase which 
is critical for proline metabolism leads to type I hyperprolinemia and is strongly 
associated with schizophrenia, autism and mental retardation. Proline has previously been 
shown to be a low affinity agonist at glutamate and glycine receptors. Because 
schizophrenia is thought to arise from glutamate receptor hypofunction and l-proline can 
act at glutamate receptors, it is necessary to understand whether increase in l-proline can 
contribute to glutamate receptor hypofunction. 
 
The aim of this research was to determine the pharmacological profile of 
physiological and pathophysiological relevant concentrations of l-proline at two 
recombinant AMPA receptors: homomeric GluR1 and heteromeric GluR1/2. Dose 
response to l-proline (concentrations of 3 µM – 10 mM) at homomeric GluR1 and 
heteromeric GluR1/2 receptors were determined and compared to saturating 
concentration of glutamate (10 mM). The effect of tonically present physiological (3 µM) 
or pathophysiological (30 µM) levels of l-proline on glutamate-evoked responses at both 
receptor types were also determined. This research supports previous findings that l-
proline is a low affinity agonist at glutamate receptors activating less than 5 % of current 
elicited by a saturating concentration of glutamate (10 mM). Tonically present 
pathophysiological concentration of l-proline was observed to lead to a decrease in 
glutamate activation of homomeric GluR1 but not heteromeric GluR1/2 receptors. This 
decrease in glutamate-induced current was blocked by the application of 0.1 mM 
cyclothiazide indicating that at pathophysiological concentrations l-proline leads to 
selective desensitization of GluR1 receptors. These actions of l-proline may be relevant 
for understanding how hyperprolinemia contributes to glutamate receptor hypofunction in 
schizophrenia. 
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CHAPTER 1. INTRODUCTION 
 
 
Proline is classified as a non-essential amino acid in adults and full-term infants 
(Miller et al. 1995; Phang et al. 2001).  It can be derived from glutamine in the liver, 
small intestine and the kidney (Bertolo and Burrin 2008). L-proline is one of the major 
amino acid constituent of extracellular fluid with a plasma concentration of 37-312 µM 
(Phang et al. 2001; Afenjar et al. 2007). The concentration of proline in the cerebrospinal 
fluid (CSF) is about a 1% of the serum concentration and ranges from 1-4 µM (Phang et 
al. 2001). Proline, like other known neurotransmitters in the central nervous system 
(CNS), is maintained in homeostasis by the activity of high affinity proline transporters. 
Thus suggesting that proline itself is a neurotransmitter (Renick et al. 1999; Phang et al. 
2001).  
 
Proline can be derived from glutamate or ornithine through the common 
precursors pyrroline-5-carboxylate (P5C) or glutamic-γ-semialdehyde (Phang et al. 
2001). The conversion of glutamate and glutamine into the intermediate P5C is catalyzed 
by the enzyme P5C synthase (Figure 1-1) (Bertolo and Burrin 2008). This step which is 
central to the synthesis/metabolism of proline is restricted to the gut (Jones 1985; Bertolo 
and Burrin 2008). Mutation of enzymes in the metabolic pathways controlling the 
synthesis (anabolism) as well as the breakdown (catabolism) of proline, results in disease 
conditions which include hyperprolinemia (Phang et al. 2001). 
 
 
1.1 Diseases of Proline Metabolism 
 
The conditions resulting from alteration in the metabolism of proline include 
hyperprolinemia type I (HPI), hyperprolinemia type II (HPII), ornithine aminotransferase 
(OAT) deficiency, hydroxyprolinemia, iminoglycinuria and Δ-1-pyrroline-5-carboxylic 
acid (P5C) synthetase deficiency (Table 1-1) (Phang et al. 2001; Mitsubuchi et al. 2008). 
Each of these conditions is caused by a mutation or deletion in one of the genes coding 
for proteins in the metabolic pathways of proline (Figure 1-1) (Bertolo and Burrin 2008; 
Mitsubishi et al. 2008).  Only three of these conditions, HPI, HPII and P5C synthase 
deficiency, however result in changes in plasma and CSF concentration of proline (Phang 
et al. 2001).  
 
Disruption of proline catabolism which results in an increase in proline 
concentration beyond the physiological range is known as hyperprolinemia (Woody et al. 
1969; Afenjar et al. 2007). Hyperprolinemia is an autosomal ressessive condition caused 
by mutations in genes that code for one of two enzymes: proline oxidase (POX) / proline 
dehydrogenase (PRODH) and ∆- 1-pyrroline-5-carboxylic dehydrogenase  (P5CDH) 
(Woody et al. 1969; Phang et al. 2001). In hyperprolinemia, a 10-fold increase plasma 
proline concentration is accompanied by an equivalent 10-fold increase in the CSF 
(Phang et al. 2001). Hyperprolinemia has been associated with schizophrenia,  
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Figure 1-1 Metabolic Pathway of Proline and Related Amino Acids 
 
Hyperprolinemia type I is caused by a mutation or deletion of the PRODH gene which 
codes for the enzyme proline oxidase that catalyses the conversion of proline to Δ-1-
proline-5-carboxylate. Hyperprolinemia type II is caused by a mutation of deletion in the 
Δ-1-proline-5-carboxylate acid dehydrogenase (P5CDH). Reprinted with permission 
from Bertolo RF, Burrin DG (2008). Comparative aspects of tissue glutamine and proline 
metabolism. J Nutr 138:2032S-2039S. 
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Table 1-1 Characteristics of human enzymes involved in proline metabolism and associated diseases 
 P5C synthase OAT POX P5C dehydrogenase Prolidase 
EC None EC26.1.13 None EC1.5.1.12 EC3.4.13.9 
Subcellular 
location 
Mitochondria 
inner membrane 
Mitochondrial 
matrix 
Mitochondrial 
inner membrane 
Mitochondrial 
matrix 
Cytoplasm 
Disease 
association 
Hypoprolinemia 
Hypocitrullinemia 
Hypoornithinemia 
Hyperammonemia 
Gyrate atrophy HPI HPII Prolidase 
deficiency 
Map location 10q24.3 to 24.6 0q26 22q11.2 1p36 19q12-13.11 
Mutations in the enzymes P5C synthase, POX and P5C dehydrogenase lead to disruption in plasma proline concentration. 
Reprinted with permission from Mitsubuchi H, Nakamura K, Matsumoto S, Endo F (2008). Inborn errors of proline 
metabolism. J Nutr 138:2016S-2020S. 
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autism, epilepsy as well as neuronal disorders which include mental retardation, epilepsy 
and delays in psychomotor development, as well as aggression in some patients (Flynn et 
al. 1989, Afenjar et al. 2007, Zinkstok et al. 2008). Thus, it is important to understand the 
actions of proline, particularly within the CNS. 
 
There are two different types of hyperprolinemia:  Hyperprolinemia Type I (HPI) 
and Hyperprolinemia Type II (HPII). Although HPI and HPII result in elevation of 
proline levels, there are differences in the magnitude of proline elevation as well as in the 
mutations that cause these disorders (Valle et al. 1976; Phang et al. 2001; Jacquet et al. 
2002). 
 
 
1.1.1 Hyperprolinemia Type I (HPI) 
 
HPI is characterized by a 5-10 fold increase in the normal concentration of plasma 
proline (Phang et al. 2001; Jacquet et al. 2002).  The increase in plasma proline level in 
HPI is due to a deletion or mutation in the proline dehydrogenase (PRODH) gene 
(Jacquet et al. 2002; Bender et al. 2005; Jacquet et al. 2005). The PRODH gene lies on 
the q arm of chromosome 22 at band 11.2 of the human genome. It encodes for the 
enzyme proline oxidase, an inner membrane mitochondria protein, which catalyzes the 
first step in the catabolism of proline to glutamate (Figure 1-1) (Campbell et al. 1997; 
Jacquet et al. 2002; Jacquet et al. 2005).  
 
22q11.2 deletion syndrome (22q11.2DS) also known as DiGeorge syndrome 
(DGS) or Velo-cardio-facial syndrome (VCFS) is associated with increases in plasma 
proline levels of individuals, higher risk for schizophrenia, as well as high prevalence of 
autism spectrum disorder (Murphy et al. 1999, Goodman et al. 2000). The syndrome, as 
the name suggests, is caused by a micro deletion of chromosome 22q11.2. Symptoms of 
22q11.2DS include congenital heart defects, seizures, palatal abnormalities, learning 
difficulties, hearing loss and in some case renal dysfunction (Shprintzen et al. 1978, 
Lipson et al. 1991, Humbertclaude et al. 2001). The cardiac defects associated with the 
syndrome appear to be generated primarily through the loss of the TBX1 gene, on 
chromosome 22q11.2 (Yagi et al. 2003). Neuropsychiatic symptoms associated with HPI 
include mental retardation, epilepsy and cognitive impairment (Di Rosa et al. 2008).  This 
suggests that elevations in brain proline levels may contribute to the psychiatric 
disturbances observed in patients with 22q11.2DS.  
 
 
1.1.2 Hyperprolinemia Type II (HPII) 
 
HPII is characterized by typically higher elevations in proline concentration than 
in HPI. Proline levels are elevated 10 -15 fold in severe HPII with plasma concentrations 
as high as 413-1883 μM (Phang et al. 2001; Afenjar et al. 2007). The increase in proline 
in HPII is accompanied by an increase in the concentration of P5C, a by-product of 
proline degradation (Valle et al. 1976). HPII is due to a mutation or deletion in the 
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ALDH4A1 gene which codes for the enzyme P5CDH.  P5CDH catalyzes the breakdown 
of P5C to the amino acid glutamate (Phang et al. 2001).  
 
 
1.2 Pathophysiology of L-Proline 
 
In rats, acute systemic administration of l-proline causes oxidative stress by 
reducing cytochrome c oxidase activity (Delwing et al. 2003; Delwing et al. 2007). When 
applied chronically l-proline has also been shown to lead to a decrease in membrane lipid 
content in the cerebellum of rats (Vianna et al. 2008), decrease in creatine kinase activity 
(Kessler et al. 2003), as well as decrease in the activities of Na+-K+-ATPase and 
acetycholinersterase (Pontes et al. 2001). The fact that l-proline administration leads to a 
deficit in learning and memory suggest that increase in l-proline levels affect the CNS 
(Davis et al, 1987).  
 
High affinity Na+-and Cl--dependent proline transporters (PROT) are widely 
expressed within a subset of glutamate neurons in the CNS (Hauptmann et al. 1983; 
Velaz-Faircloth et al. 1995). This structural localization of proline transporter, as well as 
studies showing that l-proline affects excitatory synaptic transmission suggest that l-
proline plays a role in the glutamate transmission (Cohen and Nadler 1997; Renick et al. 
1999). Direct evidence of proline activity at synapses include the ability of l-proline to 
activate glutamate and glycine receptors at concentrations above 1 mM (Henzi et al. 
1992). However, this concentration far exceeds the physiological or pathophysiological 
relevant concentrations of l-proline within the CNS (Henzi et al. 1992, Cohen and Nadler 
1997; Phang et al. 2001). At physiological and pathophysiological concentrations l-
proline potentiates field excitatory postsynaptic potential (fEPSP) in neuronal slices 
(Cohen and Nadler 1997). Due to the limited literature on the effects of l-proline at 
glutamate and glycine receptors, the spectrum of the pharmacological actions of l-proline 
towards glutamate receptors remains largely unknown. This study therefore focused on 
the effects of l-proline on two recombinant glutamate receptors.  
 
 
1.3 Glutamate Receptors: Physiological and Pathological Importance 
 
Ligand-gated glutamate receptors mediate the majority of excitatory neuronal 
transmission in the central nervous system (Dingledine et al. 1999). The amino acid 
glutamate binds to and activates a broad class of receptors collectively known as 
glutamate receptors (GluR) (Dingledine et al. 1999). The excitatory neurotransmitter 
glutamate and its receptors have been shown to be important in physiological processes 
such as neuronal plasticity as well as learning and memory (Tsien et al. 1996; Riedel et 
al. 2003).  
 
Neuronal plasticity, the ability of the brain to be modified by experiences, is a 
phenomenon underpinning learning and memory (Alkon et al. 1982; Antonov et al. 
2003). Examples of processes mediated by changes in the properties of neurons include 
long-term potentiation (LTP) (Bliss and Lomo 1973). Induction and maintenance of LTP, 
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a persistent increase in synaptic strength, is thought to be required for the formation of 
long term memories (Jones et al. 2001; Pastalkova et al. 2006; Whitlock et al. 2006).  
 
Excessive glutamate in the synaptic cleft leads to over-excitation of neurons, often 
leading to neuronal death due to excitotoxicity (Tanaka et al. 1996). Specific transporters 
maintain glutamate homeostasis by clearing excessive glutamate at synaptic cleft thereby 
shaping glutamate transmission (Diamond 2001; Katagiri et al. 2001; Hires et al. 2008). 
Glutamate-induced excitotoxicity is though to be mediated in part by the increase in 
intracellular Ca2+ concentration due to influx mediated by glutamate receptors 
(Schlaepfer and Bunge 1973, Tymianski et al. 1993). Many neurodegenerative disorders, 
such as Parkinson’s, epilepsy Alzheimer’s and Huntington’s diseases have been 
attributed to glutamate-induced excitotoxicity (Tanaka 1996; Cha et al. 1998; Ozawa 
1999). 
 
Alteration in the composition, number, subtypes and/or activity of glutamate 
receptors have also been shown to be associated with mental illnesses, neurodegenerative 
diseases such as Alzheimer’s and in other neurological disorders, such as epilepsy and 
ischemia (Meldrum 2000; Bernareggi et al. 2006; Borbely et al. 2009). Glutamate 
receptors are divided into two major groups based on the pathway that is activated upon 
binding of glutamate or other agonists to the receptors (Dingledine et al. 1999). The two 
major groups of glutamate receptors are metabotropic and ionotropic receptors as 
illustrated in Figure 1-2 (Kew and Kemp 2005). 
 
 
1.3.1 Metabotropic Glutamate Receptors 
 
The metabotropic glutamate receptor family (mGluR) currently consists of eight 
different subunits and genes and is divided into three different groups based on 
pharmacology, as well as the second messenger activated downstream to the receptors 
(Figure 1-1) (Dingledine et al. 1999). The activation of Group I mGluR family results in 
activation of second messenger signaling pathways such as phosphoinositol and results in 
an increase in cytoplasmic concentration of Ca2+ (Abe et al. 1992).  mGluRs are coupled 
to G-proteins which can be inhibitory or excitatory (Dingledine et al. 1999, Kew and 
Kemp 2005).  
 
Group I and Group II have been shown to be predominantly coupled to 
phospholipase C (PLC) signal, with the former activating and the latter inhibiting this 
pathway (Abe et al. 1992). Members of Group III mGluRs predominately inhibit Ca2+ 
channels and cyclic adenosine monophosphate (cAMP) generation (Okamoto et al. 1994). 
Members of the Group I receptors can also lead to the activation of intracellular signaling 
cascades which are independent of G-proteins and mediated by a src-tyrosine kinase 
(Heuss et al. 1999).  
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Figure 1-2 Classification of Glutamate Receptors 
 
Glutamate receptor family, showing classification of ionotrophic and metabotropic 
glutamate receptors and subunits within each class. Reprinted with permission from Kew 
J, Kemp J (2005). Ionotropic and metabotropic glutamate receptor structure and 
pharmacology. Psychopharmacology 179:4-29. 
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1.3.2 Ionotropic Glutamate Receptors 
Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels 
concentrated in postsynaptic cells in clusters called postsynaptic densities (Petralia et al. 
1994; Popratiloff et al. 1996). They are selectively permeable to Na+, K+ and 
differentially permeable to Ca2+ (Burnashev et al. 1995). The ionotropic glutamate  
receptor is tetrameric. Based on the subunit composition a particular receptor is classified 
as homomeric or heteromeric. Each of the four subunits forming the receptors is a 
membrane protein with three transmembrane domains (M1, M3 and M4) with a re-
entrant loop (M2), an intracellular C-terminus and an extracellular N- 
terminus as shown in Figure 1-3 (Bennett and Dingledine 1995; Dingledine et al. 1999; 
Anand, 2000). The agonist binding site on each subunit is formed within two segments 
(S1 and S2) in two domains of the extracellular ligand binding core (Bennet and 
Dingledine 1995; Armstrong et al. 1998; Anand 2000; Naur et al. 2005). The binding of a 
ligand to iGluRs results in conformational changes and in the opening of the ion pore, 
allowing current to flow down its electrochemical gradient (Jin et al. 2003).  
 
There are three major classes of ionotropic glutamate receptors: α-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid receptors (AMPAR), kainate receptors, and 
N-methyl-D-aspartate receptors (NMDAR) (Dingledine et al. 1999). 
 
1.3.2.1 Kainate receptors: The kainate glutamate receptor family is formed by the 
glutamate receptor subunits GluR5-7, KA1 and KA2 (Dingledine et al. 1999). The 
proteins for all five subunits are encoded for by the genes GRIK1-5 respectively 
(Dingledine et al. 1999). KA1 and KA2 subunits show a higher affinity for kainate than 
all other subunits, however they do not result in the formation of functional homomeric 
receptors (Ren et al. 2003). Kainate receptors have been implicated in diseases such as 
early onset Huntington’s, autism, schizophrenia and epilepsy (Jane et al. 2009). 
 
1.3.2.2 NMDA receptors: Unique among the iGluRs, NMDA receptors require glycine as 
a coagonist as well as their ligand, glutamate, for activation (Wafford et al. 1995). 
NMDA receptors also have a voltage-dependent Mg2+ block which is absent in other 
classes of iGluRs and are permeable to Ca2+ (Mayer and Westrook 1987; Jahr and 
Stevens 1993). The current induced by activation of NMDA receptors has a longer 
duration than that induced by other types of ionotropic glutamate receptors due to 
prolonged opening time of the receptors and slower desensitization (Gibb and Colquhoun 
1991). During desensitization the ligand remains bound to a receptor, however 
conformational changes in the receptor prevent the passage of current through the 
receptor. NMDA receptors unlike most ionotropic glutamate receptors are permeable to 
Ca2+ and therefore directly coupled to the build up of Ca2+ in the cytoplasm. Over 
activation of NMDA receptors therefore directly results in a Ca2+-dependent 
excitotoxicity (Alford et al. 1993; Christie and Jahr 2008). NMDA receptor-dependent 
Ca2+ permeability has been shown to be directly involved in the induction of LTP and in 
learning and memory through the activity of Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) (Sanhueza et al. 2007). 
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Figure 1-3 Structure of AMPA Receptor Subunit 
 
Transmemebrane topology of a single subunit of the receptor showing the three transmembrane 
domains (M1, M3 and M4), re-entrant loop (M2), the ligand-binding domains (S1 and S2), the 
intracellular C terminal and an extracellular N terminal. Reprinted with permission from 
Dingledine R, Borges K, Bowie D, Traynelis S (1999). The glutamate receptor ion 
channels. Pharmacol Rev 51:7-62. 
S1 
H2N 
COOH 
S2
flip flop 
REGION 
M1 
M2
M3 M4 
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1.3.2.3 AMPA receptors: AMPAR are tetrameric receptors composed of four subunits, 
GluR1-4 (Rosenmund et al. 1998 ).  Each subunit can exist as a ‘flip’ or flop’ which is a 
variant created by alternate splicing of a 115-base pair section of genes encoding the 
subunit. (Dingledine et al. 1999). Further posttranslational modifications can result in a 
great diversity of the receptors. Phosphorylation of amino acid residues on AMPA 
receptors by kinases such as protein kinase A (PKA), CaMKII and protein kinase C 
(PKC) provide a mechanism for controlling the activity of the receptors (Lee et al. 2003). 
The genes encoding the AMPA receptors are a single family including GRIA1, GRIA2, 
GRIA3 and GRIA4. 
 
The different subunits can combine to form homomeric or heteromeric receptors 
which have different patterns of distribution within the brain. This suggests important 
differences in the properties of each subunit and the receptors they form (Wenthold et al. 
1996; Mano and Teichiberg 1998). AMPA receptors are generally non-selective cation 
channels being permeable to Na+ and K+ and, in general, largely impermeable to Ca2+ ion 
in the CNS (Burnashev et al. 1995). Ca2+ permeability of AMPA receptors is largely 
dependent on the amino acid residue on position 586 of the GluR2 protein/subunit. This 
site is present at the conduction site in the pore formed by the subunits (Verdoon et al. 
1991). GluR2 subunits undergo subunit-specific RNA editing resulting in the conversion 
of the encoded glutamine codon (Q) to arginine (R) that determines the kinetics of the 
channel (Lomeli et al. 1994). The unedited, GluR2-Q, subunit has relatively the same 
permeability to Ca2+ as other AMPA receptor subunits, and the edited GluR2-R have a 
reduced permeability to Ca2+ (Burnashev et al. 1996). AMPAR properties including 
rectification and Ca2+ permeability differ based on subunits composition. The edited 
GluR2-R subunit is impermeable to Ca2+, and co-expression of this subunit in a 
heteromeric receptor determines the Ca2+ permeability of the receptor (Burnashev et al. 
1995; Geiger et al. 1995; Shi et al. 2001). GluR1 and GluR2 subunits of AMPA receptors 
are predominantly expressed in the hippocampus (Wenthold et al. 1996). There is a loss 
of both GluR1 and GluR2 subunit expression in the hippocampus in schizophrenia 
(Eastwood et al. 1995), therefore reductions in the activity of these receptors maybe 
important for the development of schizophrenia. 
 
Glutamate receptor I (GluR1): Glutamate receptor I (GluR1) subunits can be expressed 
as homomers or heteromers with GluR2, GluR3 and/or GluR4 subunits (Boulter et al. 
1990). Expression of GluR1 homomeric receptor varies throughout the CNS with 
preferential location in the cortex, striatum and spinal cord (Wenthold et al. 1996; 
Hermes et al. 2008; Lane et al. 2008). GluR1 is also necessary for the acquisition of 
short-term memory necessary, for acquisition of learning in a spatial memory task, as 
well as in the formation of LTP and LTD (Lee et al. 2003). Current generated by GluR1 
homomers when expressed in human embryonic kidney (HEK) cell lines is mediated by 
the flow of Na+, K+ and to a lesser extent Ca2+ (Dingledine et al. 1999). Homomeric 
GluR1 receptors are characterized by the ability to pass more current at a negative 
membrane potentials (-60 mV) than at positive membrane potentials (+60 mV) of the 
same magnitude, a property known as inward rectification (Burnashev et al. 1995). 
Homomeric GluR1 receptors are activated by agonists including AMPA, domoate, 
kainate and quisqualate (Dawson et al. 1990).  
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GluR1/2: GluR1/2 heteromeric receptors are composed of both GluR1 and GluR2 
subunits expressed as a tetramer, known as a dimer of dimers (Ayalon and Stern-bach 
2001). GluR1/2 heteromers are the major receptor type within the hippocampus and 
increases in activity and numbers of both subunits are associated with manic-like 
behavior (Wenthold et al. 1996; Du et al. 2008). When expressed in mammalian cell lines 
the homomeric GluR1/2 exhibits a non-rectifying current-voltage (I-V) relationship and 
differ from the GluR1 homomers in their lower permeability to Ca2+. These differences in 
I-V relationship can therefore be used as a means of differentiating between different 
receptors subtypes (Verdoorn et al. 1991; Burnashev et al. 1995).  
 
 
1.4 Pharmacology of AMPA Glutamate Receptors 
 
An agonist is any substance that binds to and activates a given receptor (Watkins 
2000). It can be a naturally occurring substance, or a substance that binds with as high 
affinity to a receptor as its known naturally occurring agonist (Li et al. 1997). Agonist 
binding sites present on AMPA-type glutamate receptors have been mapped using 
molecular techniques to disrupt the agonist binding sites, as well as by the analysis of 
crystalline structures of bound molecule to receptors (Hogner et al. 2002).  The AMPA 
agonist binding site has been mapped to amino acids within the S1 and S2 segments in 
both AMPA and kainate receptors (Li et al. 1995; Hogner et al. 2002). Agonists can be 
broadly divided into either full or partial agonists. The classification of an agonist is 
based on the concentration of the agonist needed to elicit a response and the ability of that 
agonist to reach a concentration at which there is no further increase in the response 
generated from the receptor (Li et al. 1997; Traynor et al. 2001). Major known agonists at 
glutamate receptors include AMPA, NMDA and kainate.  
 
A full agonist at a receptor is able to elicit a maximum affinity and/or efficacy at a 
receptor site, therefore producing a maximum response of the receptor or downstream to 
the activation of the receptor (Li et al. 1997; Traynor et al. 2001). When compared to a 
full agonist, a partial agonist elicits sub-maximal response at the receptor site (Jin et al. 
2003). It is therefore possible to classify agonists based on the electrophysiological 
response of the receptor subtype of interest (Yakushiji et al. 1989). Decrease in the 
current elicited by a partial agonist, at ionotropic glutamate receptors, is a result of a 
decrease in the receptor opening probability of the receptor (Jin et al. 2003; Maltsev et al. 
2008; Kussius and Popescu 2009). The currents produced at NMDA receptors with the 
application of a partial agonist such as alanine has been shown to desensitize faster, there 
is however no evidence that a partial agonist is able to promote the entry of the receptor 
into a desensitized state (Kussius and Popescu 2009).  
 
 
1.5 Rationale 
 
Schizophrenia a chronic mental disorder with symptoms classified into three 
broad categories: positive symptoms, negative symptoms and cognitive symptoms 
(NIMH). Over the years two major molecular basis have been proposed for 
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schizophrenia: glutamatergic hypofunction and dopaminergic hyperfunction (Mohn et al. 
1999; Lang et al. 2007; Lisman et al. 2008). Glutamate hypofunction and in particular 
AMPA receptor hypofunction is backed by studies that have shown a disruption in 
AMPA receptor regulation is associated with schizophrenia. In particular a conditional 
knock-out of GluR1 receptors results in schizophrenic-like behavior in mice (Wiedholz et 
al. 2008). The association of 22q11.2DS and hyperprolinemia to schizophrenia point to a 
possible role of l-proline in the pathology of schizophrenia (Jacquet et al. 2002; Jacquet 
et al. 2005). Hyperprolinemia has also been associated to other disease conditions such as 
autism and mental retardation (Afenjar et al. 2007; Shprintzen 2008).  
 
Proline transporters have been shown to be highly expressed in glutamatergic 
pathways in the CNS (Hauptmann et al. 1983; Renick et al. 1999). This structural 
localization of proline transporter have led to the suggestion that l-proline could play a 
role in the glutamate signal transmission pathways (Renick et al. 1999). Mutations in 
genes coding for enzymes in proline metabolism pathway results in conditions which 
include hyperprolinemia. Hyperprolinemia is also caused by errors in the catabolism of 
proline and is characterized by increases in the blood plasma levels of proline and its 
derivatives.  
 
At concentrations greater than pathophysiologically relevant concentration in the 
CNS (1 mM) l-proline has two opposite effects on membrane potential of rat dorsal horn 
neurons (Henzi et al. 1992). These effects, excitatory and inhibitory, are mediated by two 
different receptor types, the glutamate receptors and glycine receptors (Henzi et al. 1992; 
Phang et al. 2001). L-proline activates glycine receptors, NMDA receptors and non-
NMDA glutamate receptors (Henzi et al. 1992; Phang et al. 2001). Inhibitory effects of 
proline is also mediated by the d-proline isomer-activation of glycine receptors (Henzi et 
al. 1992). In spite of the low agonist affinity of l-proline for glutamate receptors, 
physiological (3 μM) and pathophysiological (30 μM) concentrations have been shown to 
potentiate glutamatergic transmission in the hippocampus (Cohen and Nadler 1997). 
Suggesting that even at very low concentrations l-proline affects glutamate transmission.  
 
These previous studies of the agonist activity of l-proline were carried out in 
native receptors in neurons where currents recorded were pharmacologically dissected. 
Thus the identity and receptor composition contributing to proline-evoked responses are 
unclear. Given the physiological and pharmacological variation in the different glutamate 
receptors, there is a need to understand the spectrum of the agonist activity of proline at 
specific glutamate receptors.  
 
Thus the aims of this study were: 
 
1. To determine the effect of subunit composition on the sensitivity of recombinant 
AMPA receptors to l-proline. 
2. To determine if desensitization contributes to the sensitivity of AMPA receptors 
to l-proline. 
3. To determine the effect of tonic l-proline levels on glutamate activation of AMPA 
receptors as a model for hyperprolinemia. 
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CHAPTER 2. MATERIALS AND METHODS 
 
 
2.1 Expression Construct and Preparation  
 
cDNA encoding for rat GluR1and GluR2 were in the pRK5 vector. pEGFP vector 
(Clontech) was used as a tranfection marker. Each construct was transformed into DH5α 
cells and plated on Luria-Bertani (LB) agar plates supplemented with antibiotic to which 
the vectors had resistant genes. LB agar was supplemented with ampicillin (50 μg/ml) for 
propagation of GluR1 and GluR2 or kanamycin (50 μg/ml) for GFP. Plates were 
incubated at 37 oC overnight. A single colony was selected from each plate and grown in 
LB broth supplemented with ampicillin or kanamycin as noted above. The culture was 
allowed to grow overnight at 37 oC in a shaking incubator at 300 rpm for 16-18 hours.  
The culture was harvested by centrifugation at 6000 rpm 4 oC for 5 mins and plasmids 
were purified with the use of a Hi-speed maxi prep kit (Qiagen; Valencia, CA). UV 
absorbance (260 nm) was used to determine the concentration of the purified DNA. The 
plasmid DNA was stored at -20 oC and later used for transfection into HEK 293 cells. 
 
 
2.2 Cell Cultures and Transfections 
 
Human embryonic kidney cells lines (HEK 293) were obtained from ATCC 
(CRL-1573, Manassas, VA). Only cells from passages 36-42 were used for experiments. 
The cells were grown in culture in media consisting of Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Invitrogen; Carlsbad, CA), 10 % fetal bovine serum (FBS) (Hyclone; 
Logan, UT) and penicillin (100 U/ml)/streptomycin (100 U/ml) (P/S) (Invitrogen; 
Carlsbad, CA). Cells were maintained in an incubator with a temperature of 37 oC; with 
an air to CO2 ratio of 95:5 %. Cells were passaged every 4-5 days by trypsinization. The 
calcium phosphate precipitation technique was used for transfection of plasmids into 
HEK 293 cells (Chen and Okayama 1987). Transfection was performed using 1 µg of 
each construct (GluR1 or GluR1 + GluR2). GFP (0.2 μg) was included as a transfection 
marker. The cells were incubated after transfection at 37 oC and washed with phosphate 
buffered saline (PBS) (Invitrogen; Carlsbad, CA) 16-18 hours after transfection. The PBS 
was subsequently replaced with fresh media. Cells were returned to the incubator and 
electrophysiological recordings were performed 24 hours later. 
 
 
2.3 Electrophysiology and Data Analysis 
 
HEK cells for each experiment were selected by microscopic visualization of GFP 
epifluorescence. Whole-cell patch clamp recording were carried out using a Multiclamp 
700A (Molecular devices; Union City, CA). Pipettes were fabricated from borosilicate 
glass (TW150F; WPI; Sarasota, FL) using a two-stage electrode puller (model PP830; 
Narshige; Tokyo, Japan). Only pipette with resistances of 2-4 MΩ were used. Pipettes 
were filled with intracellular solution containing 140 mM cesium methanesulfonate, 10 
mM HEPES, 5 mM adenosine triphosphate (sodium salt), 5 mM MgCl2, 2 mM CaCl2 and 
10 mM BAPTA at pH 7.40. The extracellular solution contained 150 mM NaCl, 5 mM 
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KCl, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM HEPES and 10 mM glucose with a pH of 7.40 
and was perfused into the recording chamber at a flow rate of 1-2 ml/min. Upon 
successful establishment of the whole-cell configuration, cells were lifted off the cover-
slip and positioned in the path of control flow line. Fast solution exchange was achieved 
by moving a series of flow pipes using a piezoelectric bimorph. Agonist-evoked currents 
were elicited every 10-30s. All experiments commenced by obtaining 5 consecutive 
stable currents in response to a saturating concentration of glutamate (10 mM; 500 ms).  
 
To determine the l-proline dose-response for recombinant AMPA receptors, l-
proline (3 μM, 30 μM, 300 μM, 3 mM or 10 mM) was applied for 500 ms with an 
interval of 10s between sweeps. Peak current evoked in response to l-proline at each 
concentration was normalized to the peak current obtained in response to glutamate. To 
assess the effect of tonic l-proline concentrations on glutamate-evoked currents, l-proline 
(0 μM, 3 μM or 30 μM) was added to both control and glutamate (10 mM) containing 
extracellular solution. Glutamate evoked current (10 mM; 500 ms) in the absence or 
presence of tonic l-proline were elicited every 30s. Peak current each for sweep was 
normalized to the peak of the initial glutamate-evoked response. For paired-pulse 
experiments, a protocol was created to deliver two pulses of glutamate (10 mM) in the 
tonic presence or absence of a pathophysiological relevant concentration of l-proline (30 
μM). The pulses were delivered for 25 ms with a delay of 200 ms between the first and 
second pulses.  
 
All currents were recorded at -60 mV.  For all cells used in data analysis, 
measured currents were normalized to the initial peak current. Currents were digitized at 
5-10 kHz and filtered at 1-2 kHz with a Digidata 1322A board and Clampex 9 software 
(Axon Instruments; Foster City, CA). Only cells with currents greater than 100 pA 
induced by 10 mM glutamate and membrane resistance ≥ 1.0 GΩ were included in the 
data analysis. I-V relationships were generated over the range -60 mV to +40 mV, in 20 
mV increments. I-V relationships were obtained at the onset of each experiment in order 
to confirm successful co-transfection of the cDNA for GluR1 and GluR2. GluR1/2 
transfected HEK cells do not show the rectification observed in HEK cells transfected 
with GluR1 alone (Figure 2-1). Only cells with a ratio of current at +40 mV to -60 mV of 
approximately 0.4 or more were included in data analysis (Burnashev et al. 1995). Data 
analysis was performed using Clampfit (Axon Instruments; Foster City, CA), and Origin 
Pro 7.0 (Microcal; Northhampton, MA). All data are displayed as mean +/- s.e.m.  
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Figure 2-1 Current-Voltage Relationship for GluR1 and GluR1/2 Transfected 
Cells 
 
HEK cells were transfected with GluR1 +/- GluR2. (A) Representative current traces for 
GluR1 at various holding potentials in response to I-V protocol (-60 mV to +40 mV). (B) 
Representative traces for GluR1/2. (C) Average I-V relationships are shown in response 
to the I-V protocol (-60 mV to +40 mV) for GluR1 (red) and GluR1/2 (black) in the 
absence (open) or presence (filled) of the desensitization blocker CTZ (100 µM) 
  A.   
  C.   
  B.    
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CHAPTER 3. RESULTS 
 
 
3.1 L-Proline is a Low Affinity Agonist at Recombinant AMPA Receptors  
 
Previous work suggests that l-proline is a very low affinity agonist at glutamate 
receptors in rat spinal cord neurons (Henzi et al. 1992). However l-proline can 
dramatically affect hippocampal excitatory transmission at much lower concentrations 
(Cohen and Nadler 1997). The pharmacological action of proline at glutamate receptors 
therefore remains unclear. This stems, in part, from the unknown receptor subtypes or 
stoichoimetry of glutamate receptors that exist in these neurons. Thus, experiments were 
designed to determine the sensitivity of l-proline at recombinant AMPA-type glutamate 
receptors. Homomeric GluR1 and heteromeric GluR1/2 receptors were examined because 
these are the prevailing AMPA receptors in the hippocampus (Wenthold et al. 1996). 
 
To determine the efficacy of l-proline as an agonist relative to glutamate, the 
dose-response relationship with l-proline was determined for GluR1 and GluR1/2 
receptors and compared to a saturating concentration of glutamate (10 mM). The 
effectiveness of l-proline in inducing current at GluR1 and GluR1/2 is dose-dependent as 
shown by its ability to induce greater currents at higher concentrations. At a 
concentration of 10 mM, l-proline elicited a current of 0.559 ± 0.141 % and 1.166 ± 
0.223 % of the initial current induced by the application of 10 mM glutamate at GluR1 
and GluR1/2 receptors respectively (Figure 3-1). Because the currents elicited with the 
application of l-proline were small, cyclothiazide (CTZ), a blocker of desensitization 
(Yamada and Tang 1993), was applied in order to enhance detection of proline-evoked 
currents. Current evoked by 10 mM l-proline at heteromeric GluR1/2 receptors were 
significantly enhanced by the presence of 100 µM CTZ (4.005 ± 0.38 %, n = 5, p < 
0.001). However, even at 10 mM l-proline generated current was less than 5 % of the 
initial 10 mM glutamate-induced current at GluR1/2 receptors. Co-application of 10 mM 
l-proline and CTZ increased current generated at GluR1 receptor to 2.045 ± 0.583 % of 
initial 10 mM glutamate-induced current.  
 
Consistent with the known actions of CTZ to increase current flow due to a 
reduction in desensitization (Yamada and Tang 1993), application of CTZ increased the 
current density in GluR1 and GluR1/2-expressing cells (Figure 3-2). Where current 
density is calculated as follows: 
 
Current density    = Total Current (pA) 
Membrane capacitance (pF) 
 
Application of CTZ was also shown to not alter the I-V relationship, a 
physiological property used in distinguishing between GluR1 and GluR1/2 receptors as 
shown in Figure 2-1. These results support previous study (Henzi et al. 1992) that have 
shown l-proline to be very low affinity agonist at glutamate receptors.  
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Figure 3-1 L-proline Dose Response for GluR1 and GluR1/2 
 
Whole-cell recordings of GluR1 and GluR1/2 receptor currents expressed in HEK 293 
cells. Currents are evoked by 500 ms application of 10 mM glutamate or 3 μM, 30 μM, 
300 μM, 3 mM and 10 mM l-proline. (A) Representative traces to the initial 10 mM 
glutamate application (black) and to application of 10 mM l-proline in GluR1 receptors 
(red). (B) Same as A, in the presence of CTZ. (C) Representative traces to the initial 10 
mM glutamate application (black) and to application of 10 mM l-proline in GluR1/2 
receptor. (D)  Same as C, in the presence of CTZ. (E) Summary graph showing the dose-
response of the l-proline peak current normalized to current induced with 10 mM 
Glutamate (not shown) for different concentration of l-proline (3 μM to 10 mM) with 
GluR1 (open square), GluR1 in the presence of CTZ (filled square), GluR1/2 (open 
triangle) and GluR1/2 in the presence of CTZ (filled triangle) where n indicated in 
parenthesis is the number of observations.  
  A.   
 E.    
  B.   
  C.     D.   
  *     
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Figure 3-2 Current Density of GluR1 and GluR1/2 
 
HEK 293 cells were transfected with GluR1 ± GluR1/2. Current densities of GluR1 and 
GluR1/2 receptors in the presence or absence of CTZ measured using glutamate (10 mM) 
as an agonist at a holding potential -60 mV.
  *     
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3.2 The Effect of Tonic L-Proline Concentrations on Recombinant AMPA Receptors 
 
In hyperprolinemia l-proline concentrations are elevated 10-fold in the 
cerebrospinal fluid to approximately 30 μM (Phang et al. 2001). This study hypothesized 
that the persistent increase in l-proline level may affect glutamate signaling at glutamate 
receptors. To test this hypothesis, the effect of tonic physiological (3 μM) and 
pathophysiological (30 μM) l-proline levels on glutamate-induced currents at GluR1 and 
GluR1/2 receptors were examined. 
 
Application of 30 µM l-proline was found to result in a statistically significant (p 
< 0.05) decrease in current generated by the application of 10 mM of glutamate (23.6 ± 
10.0 %; n = 5) (Figure 3-3). In contrast, there was no significant decrease in current 
induced with the application of 10 mM glutamate in the presence of 3 μM l-proline (1.8 ± 
8.5 %; n = 6). Application of 30 μM l-proline lead to a slight shift in the kinetics of the 
channel as shown by a delay in the activation rate with application of 10 mM of 
glutamate in the presence of 30 μM of l-proline. These findings indicate that the tonic 
presence of pathophysiological but not physiological concentration of l-proline resulted 
in a disruption of the ability of glutamate to activate homomeric GluR1 receptors. This 
result suggests that l-proline, acting as a partial agonist, reduced the agonist effect of 
glutamate by competing with glutamate for the receptors. Alternatively, l-proline could 
be responsible for driving the GluR1 receptors into a state of desensitization. These 
findings were however consistent with the reduction in agonist activity when assessed in 
the presence of a partial agonist. Thus, tonic pathophysiological concentrations of l-
proline as encountered in hyperprolinemia may contribute to glutamate receptor 
hypofunction. 
 
With heteromeric GluR1/2 receptors, there was no significant change in the 
current with the application of physiological (-3.534 ± 4.9975 %; n = 5) or 
pathophysiological (6.4360 ± 4.8742 %; n = 6) concentrations of l-proline when 
compared to control (Figure 3-4). Co-application of pathophysiological 30 μM l-proline 
with 10 mM glutamate was previously shown to lead to a slight shift in the kinetics of 
GluR1 homomeric receptors. However, under the same conditions no change in the 
kinetics of GluR1/2 heteromeric receptors was observed.  Taken together, these findings 
suggest that although l-proline induced a greater current in GluR1/2 receptors than GluR1 
receptors, tonic application of pathophysiological concentrations of l-proline selectively 
suppressed the ability of glutamate to activate homomeric GluR1 AMPA receptors. 
Given that GluR1 receptors desensitized more completely than heteromeric GluR1/2 
receptors, l-proline may preferentially drive GluR1, but not GluR1/2, receptors into a 
state of desensitization.  
 
3.3 CTZ Application Blocks the Effect of Tonic L-Proline on GluR1 Currents  
 
To test if the reduction in glutamate-induced current in the tonic presence of 
pathophysiological l-proline is due to desensitization of the receptors, CTZ was applied 
through out the experiment. The aforementioned proline-induced decrease in the current  
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Figure 3-3 The Effect of Tonic L-Proline Levels on GluR1 Currents 
 
HEK cells were transfected with GluR1 and GFP. Control whole cell recordings were 
made from cells exposed to control solution of 10 mM glutamate (black), with 
subsequent co-application of 3 μM l-proline or 30 μM l-proline (red and green 
respectively). (A-C) Representative traces during application of 10 mM glutamate (black) 
and application of 10 mM glutamate in the presence of control (0 µM), 3 µM and 30 µM 
l-proline respectively (red). (D) Summary graph showing the average time course of peak 
current normalized to the initial control pulse is plotted for coapplication of 3 µM or 30 
µM l-proline concentrations with 10 mM glutamate at GluR1. Where n indicated in 
parenthesis is the number of observations.  
  A.   
  D.   
  B.     C.    
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Figure 3-4 The Effect of Tonic L-Proline Levels on GluR1/2 Currents  
 
HEK cells were transfected with GluR1, GluR2 and GFP. Control whole cell recordings 
were made from cells exposed to control solution of 10 mM glutamate (black), 3 μM l-
proline or 30 μM l-proline (red and green respectively).  (A) Average I-V relationships 
are shown in response to I-V protocol (-60 mV to +40 mV). The I-V relationships were 
generated with the same cells used in the experiments. (B) Representative traces during 
co-application of 30 μM l-proline and 10 mM glutamate (red) and to initial 10 mM 
glutamate application (black) are shown. (C) Summary graph showing average time 
course for peak current normalized to the initial control pulse for co-application of 3 µM 
or 30 µM l-proline concentrations with 10 mM glutamate at GluR1/2 heteromeric 
receptors 
  A.     B.    
  C.   
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produced by 10 mM glutamate at GluR1 receptors was abolished by the application of 
CTZ (-3.3188 ± 4.8352 %; n = 5) when compared with control in the absence of CTZ (-
1.8860 ± 6.6879 % n = 7). Data generated for 3 μM and 30 μM l-proline are plotted on 
the same graph for visual comparison of the effect of 30 μM l-proline on GluR1 
homomeric receptors in the presence and absence of CTZ (Figure 3-5). No change in the 
kinetics of the receptor was detected upon the co-application of CTZ and 
pathophysiological concentration of l-proline. These findings suggest that the reduction 
of glutamate-evoked current by the tonic presence of a pathophysiological l-proline 
concentration was due to the ability of l-proline to drive homomeric GluR1 receptors into 
a desensitized state.  
 
 
3.4 Effect of Pathophysiological L-Proline Concentration on Paired-Pulse-Ratio in GluR1 
 
Previous studies have suggested that l-proline decreased glutamate transmission 
by reducing glutamate release in rat cerebral cortex and hippocampus (Keller et al. 1981; 
Cohen and Nadler 1997). The ability of proline to decrease glutamatergic transmission in 
the hippocampus was determined using a paired-pulse assay, in which an increase in the 
paired-pulse ratio is interpreted as a reduction in the presynaptic release (Cohen and 
Nadler 1997). However, if l-proline binds to glutamate receptors with a weak affinity, 
then a second pulse should compete off proline and generate a relatively larger current.  
 
With glutamate a paired-pulse-ratio (ratio of second pulse to the first pulse) was 
computed at 0.34 ± 0.03 (n = 5) with the co-application of pathophysiological 
concentration of l-proline (30 μM) there was a significant increase in the paired pulse 
ratio to 0.47 ± 0.04 (p < 0.05) (Figure 3-6). Therefore, an increase in the paired-pulse-
ratio in the presence of pathophysiological concentration of l-proline at GluR1 receptors 
occured. These findings suggest that the increase in paired-pulse-ratio previously 
observed in hippocampal neurons in response to pathophysiological concentrations of l-
proline may not simply be a result of altered presynaptic function but may arise, in part, 
due to l-proline-induced desensitization of GluR1. 
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Figure 3-5 CTZ Application Blocks the Effect of Tonic L-Proline on GluR1 
Currents 
 
HEK cells were transfected with GluR1 and GFP. Control whole cell recordings were 
made from cells exposed to control solution of 10 mM glutamate (black), 3 μM l-proline 
(green) or 30 μM l-proline with CTZ present (blue). (A) Representative traces during co-
application of 10 mM glutamate and 30 μM l-proline application (red) to the initial 
glutamate application (black) and at recovery (gray) in the presence of CTZ are shown. 
(B) Summary of the average time course of peak current normalized to the initial control 
pulse for co-application of 10 mM glutamate and 30 µm l-proline in the presence or 
absence of CTZ at GluR1 receptors. Where n indicated in parenthesis is the number of 
observations. 
  B.   
  A.   
  *     
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Figure 3-6 Effect of Pathophysiological L-Proline Concentration on Paired-
Pulse-Ratio in GluR1 
 
HEK cells were transfected with GluR1 and GFP exposed to 25 ms pulse of 10 mM 
glutamate (control) or 10 mM glutamate and 30 μM l-proline. (A) Representative traces 
to the initial paired pulse in the presence of control (10 mM glutamate) (black), control 
and 30 μM l-proline (red) and recovery (grey) are shown.  (B) Average of ratio of second 
pulse to the first pulse plotted against test conditions; in the presence of 10 mM glutamate 
(control), 10 mM glutamate and 30 μM l-proline and recovery. 
 
 
  A.   
  B.    
  *     
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CHAPTER 4. DISCUSSION 
 
 
4.1 L-Proline as a Partial Agonist at Recombinant AMPA Receptors 
 
Consistent with previous studies which suggested that l-proline is low affinity 
agonist at native NMDA and non-NMDA glutamate receptors (Henzi et al. 1992), the 
data presented here confirm that l-proline exhibits a low efficacy at recombinant AMPA 
receptors composed of homomeric GluR1 and heteromeric GluR1/2 receptors. Indeed, 10 
mM l-proline elicited less than 2.5 % of the current evoked by the full agonist at the same 
concentration in either of the receptors. Thus, these data are consistent with an estimated 
EC50 of above 50 mM for l-proline at native glutamate receptors and are consistent with 
l-proline acting as a partial agonist (Henzi et al. 1992). Given that l-proline generates less 
than 2.5 % of the maximum available current at a concentration of 10 mM, 
pathophysiological and physiological concentrations of l-proline will be expected to 
produce negligible direct excitation of native AMPA receptors. Rather, the actions of l-
proline at pathophysiological levels may be to dampen glutamate-mediated activation of 
AMPA receptors which is also consistent with a partial agonist profile for proline.  
 
 
4.2 L-Proline Disruption of Glutamate-Induced Current at Recombinant Glutamate 
Receptors 
 
A previous study has shown that l-proline at both physiological and 
pathophysiological potentiates glutamate transmission (Cohen and Nadler 1997). This 
effect could have been as a result of the wide repertoire of glutamate receptors expressed 
by the brain slices or the possibility that the l-proline induced potentiation of the fEPSP 
was mediated through other targets (Henzi et al. 1992; Cohen and Nadler 1997). 
Although l-proline exhibited negligible activation of the recombinant AMPARs in the 
pathophysiological to pathophysiological range, the tonic presence of pathophysiological 
l-proline selectively disrupted the ability of glutamate to activate homomeric GluR1 
receptors. Data generated from this study show a significant decrease of approximately 
24% of glutamate-induced current at GluR1 receptors with the application of a 
pathophysiological relevant concentration of l-proline. This decrease in glutamate-
induced current was however not observed in the presence of physiological concentration 
of l-proline. This suggests that the increases in l-proline level observed in 
hyperprolinemia leads to a decrease in glutamate-induced current at GluR1 receptors and 
could be relevant in the hypoglutamatergic theory of schizophrenia. Indeed, this is 
consistent with the schizophrenic behavior in animals lacking GluR1 (Wiedholz et al. 
2008). 
 
Interestingly l-proline acts differently at homomeric GluR1 and heteromeric 
GluR1/2 receptors, indicating a pharmacological difference between the two receptors.  
Moreover, the ability of homomeric GluR1 receptors to be selectively targeted may be 
particularly relevant for schizophrenia. Indeed these receptors tend to be preferentially 
expressed on interneurons (Geiger et al. 1995; Rossi et al. 2008). Reduction in the 
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activity of these neurons has been proposed to be critical for schizophrenia (Belforte et al. 
2010). 
 
 
4.3 L-Proline Desensitization of GluR1 Receptors 
 
The proline-induced reduction in glutamate-induced current observed at GluR1 
receptors was abolished by the application of CTZ. These findings, as well as data 
generated from the paired-pulse ratio experiment suggest l-proline acts by binding at 
homomeric GluR1 receptors and at least at pathophysiological concentration by inducing 
significant desensitization of the receptor. Interestingly, the increase in Paired-pulse-ratio 
due to pathophysiological l-proline described by Cohen and Nadler (1997) was 
approximately 50 %, which is similar to the approximately 38 % increased observed in 
response to a similar protocol in the recombinant system employed. Thus, contrary to a 
previous study suggesting that the l-proline-induced increase in paired-pulse ratio 
observed on native receptors in hippocampal slices is through a reduction in pre-synaptic 
glutamate release; the data presented here indicate a postsynaptic mechanism by which l-
proline induces a decrease in glutamate-induced current at GluR1 receptor through 
desensitization of the receptor. This is particularly interesting as a recent study has 
suggested that Ca2+-permeable AMPA receptors (which are presumably GluR1 
homomers) reside in the perisynaptic space (He et al. 2009). The presence of these Ca2+-
permeable AMPA receptors are preferentially revealed by paired pulse stimulation 
protocols (He et al. 2009). Thus, the ability of l-proline to induce an increase in paired 
pulse ratio is consistent with the selective regulation of homomeric GluR1 AMPA 
receptors described here.  
 
As shown in this study l-proline has differential effect on glutamate-induced 
current at two different AMPA receptors, thus the possibility exists that l-proline acts at 
other types of glutamate receptors including NMDA receptors which are important in a 
subunit specific manner for learning and memory. Indeed, one can expect these findings 
to be extended to other glutamate receptors and thus, the possibility that l-proline could 
also account for glutamate hypofunction at these receptors.   
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CHAPTER 5. CONCLUSION 
 
 
The experiments carried out in this study were designed with a view to 
determining the role of l-proline as an agonist, as well as the implications of 
hyperprolinemia at two recombinant AMPA receptors. Specifically, to determine the 
differential effect of tonically present physiological versus pathophysiological 
concentration of l-proline on the ability of glutamate to bind to and activate GluR1 
homomeric and GluR1/2 heteromeric receptors. A decrease in glutamate-induced current 
was observed with the application of pathophysiological concentration of l-proline (30 
μM) when compared to the physiological concentration (3 μM). This decrease was not 
observed with the same concentration in GluR1/2 heteromeric receptors. L-proline was 
shown to induce a larger current at GluR1/2 heteromeric receptors than at GluR1 
homomeric receptors, however the current induced at 30 μM (pathophysiological 
concentration) of l-proline is shown to be statistically insignificant.  
 
The reduction in glutamate-induced current in the tonic presence of 
pathophysiological concentration of l-proline was shown to be due to desensitization of 
the receptor. The differences in the ability of l-proline to induce desensitization at GluR1 
homomeric receptors and its ability to induce currents at GluR1/2 heteromeric and GluR1 
homomeric receptors may provide a foundation to the understanding of how l-proline 
affects glutamate transmission. The ability of pathophysiological concentrations of l-
proline to induce a decrease in glutamate-induced current at homomeric GluR1 receptors 
may be a relevant mechanism by which hyperprolinemia contributes to schizophrenia.  
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